JP3219096B2 - ｎ―グリコフロール類及びｎ―エチレングリコール類を含有する医薬製剤 - Google Patents

ｎ―グリコフロール類及びｎ―エチレングリコール類を含有する医薬製剤

Info

Publication number
JP3219096B2
JP3219096B2 JP50970691A JP50970691A JP3219096B2 JP 3219096 B2 JP3219096 B2 JP 3219096B2 JP 50970691 A JP50970691 A JP 50970691A JP 50970691 A JP50970691 A JP 50970691A JP 3219096 B2 JP3219096 B2 JP 3219096B2
Authority
JP
Japan
Prior art keywords
analogs
composition according
derivatives
formula
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP50970691A
Other languages
English (en)
Japanese (ja)
Other versions
JPH05507085A (ja
Inventor
ベクゴール，エリック
キズラルソン，スベインイエリィ
チュールマン イオルキエール，ロルフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda AS
Original Assignee
Nycomed Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK117090A external-priority patent/DK117090D0/da
Priority claimed from DK207590A external-priority patent/DK207590D0/da
Application filed by Nycomed Pharma AS filed Critical Nycomed Pharma AS
Publication of JPH05507085A publication Critical patent/JPH05507085A/ja
Application granted granted Critical
Publication of JP3219096B2 publication Critical patent/JP3219096B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP50970691A 1990-05-10 1991-05-03 ｎ―グリコフロール類及びｎ―エチレングリコール類を含有する医薬製剤 Expired - Fee Related JP3219096B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DK1170/90 1990-05-10
DK117090A DK117090D0 (da) 1990-05-10 1990-05-10 Composition for intranasal administration of biol ogically active benzodiazepine compounds
DK2075/90 1990-08-30
DK207590A DK207590D0 (da) 1990-08-30 1990-08-30 Farmaceutisk praeparat

Publications (2)

Publication Number Publication Date
JPH05507085A JPH05507085A (ja) 1993-10-14
JP3219096B2 true JP3219096B2 (ja) 2001-10-15

Family

ID=26065326

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50970691A Expired - Fee Related JP3219096B2 (ja) 1990-05-10 1991-05-03 ｎ―グリコフロール類及びｎ―エチレングリコール類を含有する医薬製剤

Country Status (14)

Country Link
US (2) US5428006A (cs)
EP (1) EP0532546B1 (cs)
JP (1) JP3219096B2 (cs)
CN (1) CN1056812A (cs)
AT (1) ATE164080T1 (cs)
AU (3) AU7880991A (cs)
CS (1) CS136191A3 (cs)
DE (1) DE69129110T2 (cs)
DK (1) DK0532546T3 (cs)
ES (1) ES2117642T3 (cs)
IE (1) IE911577A1 (cs)
IL (1) IL98089A0 (cs)
PT (1) PT97610A (cs)
WO (1) WO1991016929A1 (cs)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7880991A (en) * 1990-05-10 1991-11-27 Novo Nordisk A/S A pharmaceutical preparation containing n-glycofurols and n-ethylene glycols
DE69231890T2 (de) 1991-12-19 2002-03-28 Univ Saskatchewan Saskatchewan Desikkation von gymnosperm somatischen embryonen
GB2267435A (en) * 1992-06-01 1993-12-08 British Tech Group Factor VIII
JP3756512B2 (ja) * 1992-09-21 2006-03-15 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 徐放性タンパク質製剤
US5743250A (en) 1993-01-29 1998-04-28 Aradigm Corporation Insulin delivery enhanced by coached breathing
US6024090A (en) * 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
US5915378A (en) * 1993-01-29 1999-06-29 Aradigm Corporation Creating an aerosolized formulation of insulin
US5873358A (en) * 1993-01-29 1999-02-23 Aradigm Corporation Method of maintaining a diabetic patient's blood glucose level in a desired range
US6131567A (en) * 1993-01-29 2000-10-17 Aradigm Corporation Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
US5970973A (en) * 1993-01-29 1999-10-26 Aradigm Corporation Method of delivering insulin lispro
US5888477A (en) * 1993-01-29 1999-03-30 Aradigm Corporation Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin
EP0621033A1 (en) * 1993-04-20 1994-10-26 Nostras S.A. Antibiotic composition containing oxytetracycline and glycofurol
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
DK0724885T3 (da) * 1993-10-21 2002-05-21 Hisamitsu Pharmaceutical Co Pernasal sammensætning og pernasalt præparat indeholdende dette
GB9409778D0 (en) 1994-05-16 1994-07-06 Dumex Ltd As Compositions
WO1996019198A1 (en) 1994-12-22 1996-06-27 Astra Aktiebolag Aerosol drug formulations
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
JP3506714B2 (ja) * 1995-02-22 2004-03-15 ノバルティス・アクチエンゲゼルシャフト １−アリール−２−アシルアミノ−エタン化合物およびニューロキニン特にニューロキニン１アンタゴニストとしてのそれらの用途
NZ331238A (en) * 1996-03-05 2000-05-26 Orquest Inc Method of promoting bone growth with hyaluronic acid and growth factors (bFGF)
US6221854B1 (en) 1996-03-05 2001-04-24 Orquest, Inc. Method of promoting bone growth with hyaluronic acid and growth factors
US6645945B1 (en) 1996-03-05 2003-11-11 Depuy Acromed, Inc. Method of treating diseased, injured or abnormal cartilage with hyaluronic acid and growth factors
US20110207666A1 (en) * 1996-03-05 2011-08-25 Depuy Spine, Inc. Method of promoting bone growth with hyaluronic acid and growth factors
US5955098A (en) * 1996-04-12 1999-09-21 Flemington Pharmaceutical Corp. Buccal non polar spray or capsule
US5869082A (en) * 1996-04-12 1999-02-09 Flemington Pharmaceutical Corp. Buccal, non-polar spray for nitroglycerin
US6051558A (en) * 1997-05-28 2000-04-18 Southern Biosystems, Inc. Compositions suitable for controlled release of the hormone GnRH and its analogs
US7799337B2 (en) * 1997-07-21 2010-09-21 Levin Bruce H Method for directed intranasal administration of a composition
US20050180923A1 (en) * 1997-10-01 2005-08-18 Dugger Harry A.Iii Buccal, polar and non-polar spray containing testosterone
US20050287075A1 (en) * 1997-10-01 2005-12-29 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20040136914A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US20030082107A1 (en) * 1997-10-01 2003-05-01 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
US20040141923A1 (en) * 1997-10-01 2004-07-22 Dugger Harry A. Buccal, polar and non-polar spray containing alprazolam
US20050281752A1 (en) * 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US7632517B2 (en) * 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
US20030190286A1 (en) * 1997-10-01 2003-10-09 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma
US20030095925A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
US20050163719A1 (en) * 1997-10-01 2005-07-28 Dugger Harry A.Iii Buccal, polar and non-polar spray containing diazepam
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20090162300A1 (en) * 1997-10-01 2009-06-25 Dugger Iii Harry A Buccal, polar and non-polar spray containing alprazolam
CA2306024C (en) * 1997-10-01 2011-04-26 Flemington Pharmaceutical Corporation Buccal, polar and non-polar spray or capsule
US20050002867A1 (en) * 1997-10-01 2005-01-06 Novadel Pharma Inc. Buccal, polar and non-polar sprays containing propofol
US20030185761A1 (en) * 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20040136913A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing sumatriptan
US20030077228A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders
US20040136915A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing atropine
US20030095927A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
US6391282B1 (en) * 1997-11-10 2002-05-21 Flemington Pharmaceutical Corp. Antihistamine sprays and ointments for relief of delayed contact dermatitis
GB9822170D0 (en) * 1998-10-13 1998-12-02 Danbioyst Uk Ltd Novel formulations of fexofenadine
WO2000074651A1 (de) * 1999-06-02 2000-12-14 Hexal Ag Pharmazeutische zusammensetzung zur nasalen anwendung von wasserunlöslichen und/oder schwer wasserlöslichen wirkstoffen
JP2005505491A (ja) * 1999-06-02 2005-02-24 ヘキサル・アクチェンゲゼルシャフト 水溶性活性物質の鼻腔内投与用医薬組成物
WO2000074736A1 (en) 1999-06-04 2000-12-14 Delrx Pharmaceutical Corporation Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
US7176279B2 (en) * 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US6579968B1 (en) 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
AU778896B2 (en) * 1999-07-26 2004-12-23 Sk Biopharmaceuticals Co., Ltd. Transnasal anticonvulsive compositions and modulated process
FR2796843B1 (fr) * 1999-07-29 2003-05-09 So Ge Val Sa Composition antipyretique concentree et stabilisee a usage veterinaire destine a etre incorporee a l'alimentation des animaux ainsi que procede d'incorporation de cette composition a l'eau de boisson d'animaux
MXPA02003176A (es) 1999-10-04 2002-09-30 Shearwater Corp Neuropeptidos estabilizados por polimero.
WO2001056594A1 (en) 2000-02-04 2001-08-09 Unigene Laboratories, Inc. Nasal calcitonin formulations
US6706272B2 (en) * 2000-03-08 2004-03-16 Shinto Fine Co., Ltd. Method for denaturing allergens
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
IL137559A (en) * 2000-07-27 2006-12-31 Amnon Sintov A system for administering drugs through the skin
DE60133203T3 (de) * 2000-07-31 2012-02-23 Nycomed Danmark Aps Fentanyl Zusammensetzung für nasale Anwendung
EP1315533A4 (en) * 2000-08-15 2007-06-27 Univ Kentucky Res Found PROGRAMMABLE MULTI-DOSE DEVICE FOR INTRANASAL MEDICINE ADMINISTRATION
AU2002238106A1 (en) * 2001-02-13 2002-08-28 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
US20040176359A1 (en) * 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US7342089B2 (en) * 2001-07-11 2008-03-11 Palatin Technologies, Inc. Cyclic peptides for treatment for cachexia
US7345144B2 (en) * 2001-07-11 2008-03-18 Palatin Technologies, Inc. Cyclic peptides for treatment of cachexia
DK1429731T3 (da) * 2001-09-19 2007-05-14 Elan Pharma Int Ltd Nanopartikelformuleringer indeholdende insulin
US20050227911A1 (en) * 2001-09-28 2005-10-13 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules
US20050233003A1 (en) * 2001-09-28 2005-10-20 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of salicylic acid
US6878693B2 (en) * 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
AU2002365083A1 (en) * 2001-10-17 2003-06-30 Ganado Research, L.L.C. Composition and method to treat viral bacterial and parasitic infections and infestations
US7700851B2 (en) * 2001-11-13 2010-04-20 U.S. Smokeless Tobacco Company Tobacco nicotine demethylase genomic clone and uses thereof
US6641799B2 (en) 2002-04-03 2003-11-04 Nos Spray, Inc. Nasal spray for decongesting nasal passages
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
AU2003248888A1 (en) * 2002-07-09 2004-01-23 Palatin Technologies, Inc. Peptide composition for treatment of sexual dysfunction
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
WO2004084859A2 (en) 2003-03-21 2004-10-07 Nastech Pharmaceutical Company Inc. Nasal calcitonin formulations containing chlorobutanol
BRPI0408925A (pt) * 2003-03-31 2006-04-04 Alza Corp veìculos de fase simples não-aquosos e formulações utilizando tais veìculos
WO2004100899A2 (en) * 2003-05-13 2004-11-25 The Mclean Hospital Corporation Use of secretin in treatments of disorders associated with the amygdala
JP2006527764A (ja) * 2003-06-17 2006-12-07 エスケー コーポレイション ジアゼパムを含有する経鼻マイクロエマルジョン
GB0400804D0 (en) * 2004-01-14 2004-02-18 Innoscience Technology Bv Pharmaceutical compositions
US6974187B2 (en) * 2004-01-28 2005-12-13 Tachi-S Co., Ltd. Vehicle seat structure
CA2581564C (en) * 2004-10-01 2017-01-03 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Compounds that modulate trh actions
CN101123957B (zh) * 2005-02-01 2010-12-08 特罗伊卡药品有限公司 双氯芬酸及其药学上可接受盐的注射剂
ES2490595T3 (es) 2005-02-17 2014-09-04 Abbott Laboratories Administración transmucosal de composiciones de fármacos para tratar y prevenir trastornos en animales
US20070021411A1 (en) * 2005-05-11 2007-01-25 Cloyd James C Supersaturated benzodiazepine solutions and their delivery
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US8247530B2 (en) * 2005-11-08 2012-08-21 Palatin Technologies, Inc. N-alkylated cyclic peptide melanocortin agonists
US8580746B2 (en) * 2006-03-30 2013-11-12 Palatin Technologies, Inc. Amide linkage cyclic natriuretic peptide constructs
AU2007233123A1 (en) * 2006-03-30 2007-10-11 Palatin Technologies, Inc. Linear natriuretic peptide constructs
MX2008012663A (es) * 2006-03-30 2008-10-13 Palatin Technologies Inc Constructos ciclicos de peptidos natriureticos.
WO2007123955A2 (en) * 2006-04-19 2007-11-01 Novadel Pharma Inc. Stable hydroalcoholic oral spray formulations and methods
TW200824693A (en) * 2006-08-28 2008-06-16 Jazz Pharmaceuticals Inc Pharmaceutical compositions of clonazepam and methods of use thereof
CA2673049C (en) * 2006-12-22 2016-02-23 Novadel Pharma Inc. Stable anti-nausea oral spray formulations and methods
US20080275030A1 (en) * 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
CN106389330A (zh) 2007-01-19 2017-02-15 哈南亚有限公司 用于递送治疗剂的方法和组合物
WO2008141264A1 (en) * 2007-05-10 2008-11-20 Novadel Pharma Inc. Anti-insomnia compositions and methods
BRPI0811319A2 (pt) 2007-05-25 2015-02-10 Tolmar Therapeutics Inc Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento
TW200922635A (en) * 2007-08-31 2009-06-01 Archimedes Dev Ltd Non-aqueous pharmaceutical compositions
US8507468B2 (en) 2007-10-02 2013-08-13 Robert Orr Intranasal anti-convulsive compositions and methods
WO2009046444A2 (en) * 2007-10-05 2009-04-09 Mdrna, Inc. Formulation for intranasal administration of diazepam
US7985325B2 (en) * 2007-10-30 2011-07-26 Novellus Systems, Inc. Closed contact electroplating cup assembly
JP5613657B2 (ja) 2008-03-28 2014-10-29 ヘイル バイオファーマ ベンチャーズ，エルエルシー ベンゾジアゼピン組成物の投与
US8473062B2 (en) * 2008-05-01 2013-06-25 Autonomic Technologies, Inc. Method and device for the treatment of headache
KR101517415B1 (ko) 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
WO2010065801A1 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Amine substituted piperazine melanocortin receptor-specific compounds
WO2010065799A2 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Amine substituted piperidine melanocortin receptor-specific compounds
WO2010065802A2 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Substituted pyrrolidine or imidazolidine melanocortin receptor-specific compounds
US8412336B2 (en) 2008-12-29 2013-04-02 Autonomic Technologies, Inc. Integrated delivery and visualization tool for a neuromodulation system
US9320908B2 (en) 2009-01-15 2016-04-26 Autonomic Technologies, Inc. Approval per use implanted neurostimulator
US8494641B2 (en) 2009-04-22 2013-07-23 Autonomic Technologies, Inc. Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism
EA020959B1 (ru) 2009-06-08 2015-03-31 Палатин Текнолоджиз, Инк. Пептиды, специфичные к меланокортиновым рецепторам
KR101853606B1 (ko) 2009-07-06 2018-05-03 사노피-아벤티스 도이칠란트 게엠베하 메티오닌을 함유하는 수성 인슐린 제제
DK2498802T3 (en) 2009-11-13 2015-04-13 Sanofi Aventis Deutschland Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
KR101337322B1 (ko) 2009-11-13 2013-12-06 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
ES2606554T3 (es) 2010-08-30 2017-03-24 Sanofi-Aventis Deutschland Gmbh Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
CN105853348B (zh) 2011-03-10 2019-08-30 Xeris药物公司 肠胃外注射用稳定溶液
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
DK3415139T3 (da) 2011-06-14 2022-06-20 Neurelis Inc Administration af benzodiazepin
PL2750699T3 (pl) 2011-08-29 2015-12-31 Sanofi Aventis Deutschland Kombinacja farmaceutyczna do stosowania w kontroli glikemii u pacjentów z cukrzycą typu 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
US9534018B2 (en) 2012-03-13 2017-01-03 Tensive Controls Inc. Melanocortin analogs having enhanced activity and transport
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
AU2015300944B2 (en) 2014-08-06 2019-07-11 Xeris Pharmaceuticals, Inc. Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
WO2016044683A1 (en) 2014-09-19 2016-03-24 Tensive Controls, Inc. Anti-microbial peptides
AU2015359376B2 (en) 2014-12-12 2021-09-09 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
BR112019024987A2 (pt) 2017-06-02 2020-06-16 Xeris Pharmaceuticals, Inc. Formulações de fármaco de molécula pequena resistente à precipitação
HUE066356T2 (hu) 2017-08-24 2024-07-28 Novo Nordisk As GLP-1 készítmények és alkalmazásaik
CA3167217A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
US11590209B2 (en) 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension
PE20221575A1 (es) 2020-02-18 2022-10-06 Novo Nordisk As Formulaciones farmaceuticas
CN116940358A (zh) 2021-01-12 2023-10-24 度勒科特公司 持续释放药物递送系统和有关的方法
US12599611B2 (en) 2021-06-10 2026-04-14 Neurelis, Inc. Methods and compositions for treating seizure disorders in pediatric patients

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2528516A1 (de) * 1974-07-05 1976-01-22 Sandoz Ag Neue galenische zubereitung
US4153689A (en) * 1975-06-13 1979-05-08 Takeda Chemical Industries, Ltd. Stable insulin preparation for nasal administration
GB1554157A (en) * 1975-06-13 1979-10-17 Takeda Chemical Industries Ltd Stable insulin preparation for intra nasal administration
CA1196284A (en) * 1982-05-28 1985-11-05 Joshua Oduro-Yeboah Pharmaceutical formulations
HU190841B (en) * 1983-02-04 1986-11-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for the production of cyclodextrin polymers swelling in water quickly and to a high extent
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
JPS61267528A (ja) * 1984-11-26 1986-11-27 Yamanouchi Pharmaceut Co Ltd 吸収促進剤を含有するカルシトニン経鼻剤
EP0278997A1 (de) * 1987-02-17 1988-08-24 Siegfried Aktiengesellschaft Azapropazon-Rektalkapseln
US4950664A (en) * 1988-09-16 1990-08-21 Rugby-Darby Group Companies, Inc. Nasal administration of benzodiazepine hypnotics
JP2911496B2 (ja) * 1989-09-11 1999-06-23 帝國製薬株式会社 生理活性ポリペプチド含有高吸収性経膣剤
DE3939492A1 (de) * 1989-11-29 1991-06-06 Mack Chem Pharm Pharmazeutische zubereitungen
AU7880991A (en) * 1990-05-10 1991-11-27 Novo Nordisk A/S A pharmaceutical preparation containing n-glycofurols and n-ethylene glycols

Also Published As

Publication number Publication date
AU654950B2 (en) 1994-12-01
AU1358695A (en) 1995-06-01
DE69129110T2 (de) 1998-12-10
DE69129110D1 (de) 1998-04-23
IL98089A0 (en) 1992-06-21
IE911577A1 (en) 1991-11-20
CN1056812A (zh) 1991-12-11
JPH05507085A (ja) 1993-10-14
PT97610A (pt) 1992-01-31
WO1991016929A1 (en) 1991-11-14
EP0532546B1 (en) 1998-03-18
AU687496B2 (en) 1998-02-26
AU7643591A (en) 1991-11-14
US5693608A (en) 1997-12-02
AU7880991A (en) 1991-11-27
ES2117642T3 (es) 1998-08-16
DK0532546T3 (da) 1998-12-28
EP0532546A1 (en) 1993-03-24
ATE164080T1 (de) 1998-04-15
CS136191A3 (en) 1992-04-15
US5428006A (en) 1995-06-27

Similar Documents

Publication Publication Date Title
EP0532546B1 (en) A pharmaceutical preparation containing n-glycofurols and n-ethylene glycols
US5397771A (en) Pharmaceutical preparation
JP6295314B2 (ja) 治療薬を送達するための方法および組成物
US10052333B2 (en) Methods and systems for the delivery of a therapeutic agent
AU2007290589B2 (en) Pharmaceutical compositions of clonazepam and methods of use thereof
NO338665B1 (no) Doseringssystem med kontrollert frigivning for nasale anvendelser
US20100034880A1 (en) Pharmaceutical compositions based on a microemulsion
JP2017155060A5 (cs)
WO1995011042A1 (en) Pernasal composition and pernasal preparation containing the same
EP1408896B1 (en) Pharmaceutical composition
CA2082495C (en) A pharmaceutical preparation containing n-glycofurols and n-ethylene glycols
Chien Nasal Drug Delivery
JPH0717520B2 (ja) 鼻腔内投与用薬剤組成物
JP3597233B2 (ja) 経鼻組成物及びそれを含有する経鼻製剤
HK1230483A1 (en) Methods and compositions for the delivery of a therapeutic agent
AU2018202245A1 (en) Methods and compositions for the delivery of a therapeutic agent

Legal Events

Date Code Title Description
S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20080810

Year of fee payment: 7

LAPS Cancellation because of no payment of annual fees